BOSENTAN CIPLA bosentan 125 mg (as monohydrate) tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 125 mg (as monohydrate) tablet blister pack

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 125 mg (as monohydrate) tablet bottle Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 125 mg (as monohydrate) tablet bottle

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 62.5 mg (as monohydrate) tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 62.5 mg (as monohydrate) tablet blister pack

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 62.5 mg  (as monohydrate) tablet bottle Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 62.5 mg (as monohydrate) tablet bottle

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

PERUBATAN HOMEOPATHY RADZIAH NASOBETT TABLET 200MG Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

perubatan homeopathy radziah nasobett tablet 200mg

perubatan homeopathy raziah - mentha piperita 30c; lemna minor 30c; agnus cactus 30c; agaricus muscarius 30c -

PERUBATAN HOMEOPATHY RADZIAH DIAMILIGON TABLET 200MG Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

perubatan homeopathy radziah diamiligon tablet 200mg

perubatan homeopathy raziah - syzygium jambolanum 30c; momordica balasmina 30c; cantharis vesicatoria 30c; abroma augusta 30c -

PERUBATAN HOMEOPATHY RADZIAH GASTERHEAL TABLET 180MG Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

perubatan homeopathy radziah gasterheal tablet 180mg

perubatan homeopathy raziah - staphysagria macrocarpa 30c; colocynthis vulgaris 30c; carbo vegetabilis 30c -